We previously demonstrated clinical safety of the tumour-selective immunocytokine L19-IL2, consisting of the anti-ED-B scFv L19 antibody coupled to IL2, combined with stereotactic ablative radiotherapy (SABR).This investigator-initiated, multicentric, randomised controlled open-label phase II clinical ...
Learn more about SABR and its use as a radiation therapy treatment for certain cancer types. Stereotactic Ablative Radiation Therapy (SABR) SABR aims to specifically target tumours in the body with high doses of radiation therapy, while limiting the dose to surrounding healthy organs.1,2 ...
Stereotactic ablative body radiotherapy (SABR) represents a technological breakthrough in radiotherapy technique, with proven benefits to patients in terms of improved tumour control and overall survival. The key components of SABR are described. The current evidence base for SABR for the treatment of ...
Image-guided stereotactic ablative radiotherapy (SABR; also called stereotactic body radiotherapy) delivers focused, ablative radiation doses to a target while minimizing the dose to surrounding critical normal structures. It has produced local control rates in excess of 90% for patients with early stag...
Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020;38:2830–8. Article PubMed PubMed Central Google Scholar Francolini G, Gaetano Allegra A, Detti B, Di Cataldo V, Cai...
The use of stereotactic ablative body radiotherapy (SABR) in patients with early-stage non–small cell lung cancer (NSCLC) has been shown to be safe and effective.1, 2 In the present era, SABR is commonly discussed as an alternative to surgery based on the results of various evaluations.2...
摘要原文 To update the 2012 UK stereotacticablative radiotherapy (SABR) Consortium survey and assess the development of SABR services across the UK over the past 6 years. Use the results to share practice and continue to drive forward technique development, aid standardization and by highlighting iss...
SABR: stereotactic ablative body radiotherapy RCC: renal cell carcinoma IVC: inferior vena cava TT: tumor thrombus AE: adverse effect CTCAE: Common Terminology Criteria for Adverse Events GTV: gross tumor volume PTV: planning target volume BMI: body mass index ECOG: Eastern Cooperative...
Stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiotherapy, is a rapidly emerging technique for the treatment of oligometastatic disease. SABR's role in the treatment of stage I lung cancer in patients is well established for inoperable patients,10 while for patients who...
To assess the feasibility and safety of stereotactic ablative body radiotherapy (SABR) for renal cell carcinoma (RCC) in patients unsuitable for surgery. Secondary objectives were to assess oncological and functional outcomes.This was a prospective interventional clinical trial with institutional ethics boa...